The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has announced a proposed issue of 10,228,239 ordinary fully paid securities, with a planned issue date of January 7, 2025. This strategic move may help the company raise capital, potentially enhancing its financial position and ability to invest in its product pipeline, thereby strengthening its market presence and shareholder value.
More about Mesoblast Limited
Mesoblast Limited is a biopharmaceutical company that focuses on developing cellular medicines for inflammatory diseases, cardiovascular conditions, and orthopedic disorders. The company aims to leverage its proprietary technology platform to address significant unmet medical needs in these areas.
YTD Price Performance: 0%
Average Trading Volume: 107,759
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.26B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.